Blog
RSS FeedPosted by Michael Wonder on 26 May 2020
Medicines New Zealand consulting on a new generation medicines policy
26 May 2020 - The New Zealand Institute of Economic Research have produced a discussion paper for Medicines New Zealand ...
Posted by Michael Wonder on 20 May 2020
Insurers back plan for private health plans to cover kids up to age 30
20 May 2020 - The Morrison government is considering a proposal to allow young Australians to stay on their parents' ...
Posted by Michael Wonder on 16 Apr 2020
A strategy for improving U.S. health care delivery — conducting more randomised, controlled trials
16 April 2020 - Despite the prominence of randomised, controlled trials in medical research, they have rarely been used to evaluate ...
Posted by Michael Wonder on 06 Apr 2020
A coronavirus casualty: delay in comprehensive drug pricing legislation
6 April 2020 - As numbers of new cases of coronavirus mount as well as an increasing death toll, the ...
Posted by Michael Wonder on 30 Mar 2020
Is it worthwhile having private health insurance during the coronavirus epidemic?
31 March 2020 - Major private health funds have delayed scheduled premium hikes and offered fee relief for policyholders who ...
Posted by Michael Wonder on 14 Mar 2020
Insulin costs may be capped in a Medicare program
11 March 2020 - If drug companies and insurers agree to participate, the Trump administration proposes limiting insulin costs to $35 ...
Posted by Michael Wonder on 09 Mar 2020
PhRMA: federal biosimilar payment policies are having a positive effect
4 March 2020 - Katie Verb, director of policy and research for the biopharmaceutical industry group PhRMA, discusses recent policy changes ...
Posted by Michael Wonder on 09 Mar 2020
HHS finalises historic rules to provide patients more control of their health data
9 March 2020 - Final rules require access to health information, spur innovation and aim to end information blocking ...
Posted by Michael Wonder on 08 Mar 2020
Five years on, biosimilars need support from all health care players
6 March 2020 - Today marks a milestone for the U.S. biosimilar market: the FDA approved our first biosimilar, Sandoz’s ...
Posted by Michael Wonder on 08 Mar 2020
Price controls imposed by shortsighted politicians keep new life-saving drugs out
5 March 2020 - Politicians need to step outside the Ottawa bubble and understand how their policies impact the lives of ...
Posted by Michael Wonder on 05 Mar 2020
How would single payer health care in the US impact pharma? A pricing perspective.
5 March 2020 - The US health care system is the most complicated amongst advanced industrialised countries. ...
Posted by Michael Wonder on 04 Mar 2020
Social spending to improve population health — does the United States spend as wisely as other countries?
5 March 2020 - If U.S. social spending levels are similar to those of other high-income countries and health care spending ...
Posted by Michael Wonder on 04 Mar 2020
Joe Biden's health care plan would spend $750 billion more on Obamacare and cap drug price inflation
4 March 2020 - Joe Biden’s sweeping success on Super Tuesday doesn’t just establish him as the 2020 Democratic frontrunner. ...
Posted by Michael Wonder on 03 Mar 2020
The coronavirus could help pharma reset its reputation in Washington
3 March 2020 - The coronavirus outbreak could be the pharmaceutical industry’s ticket to saving its reputation in Washington. ...
Posted by Michael Wonder on 27 Feb 2020
First National Action Plan for rare diseases
26 February 2020 - The Australian Government will provide up to $3.3 million for activities to implement the first National Strategic ...